Related Experiment Video
Updated: Jan 9, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
The unseen risk of Ozempic: NAION and vision damage
Noor Ul Ain Saleem1, Mishaim Khan1, Christian Tague2
1FMH College of Medicine and Dentistry, Lahore, Pakistan.
Abstract:
Ozempic (semaglutide) was first authorized to treat type 2 diabetes, but because of its appetite-suppressing properties, it has become popular off-label for weight loss. According to clinical investigations, GLP-1 significantly decreases blood sugar and helps people lose weight. Approximately 15 million persons in the United States are currently taking GLP-1 drugs. Off-label use is becoming more common, which raises worries about potential health hazards and significant side effects such as non-arteritic anterior ischemic optic neuropathy (NAION). According to a study, 6.7% of people who were overweight and 8.9% of those with diabetes who took semaglutide had NAION. The FDA issued a warning regarding counterfeit and compounded products while approving semaglutide for weight loss under the Wegovy® brand. Unsupervised usage and problems with diabetes accessibility raise ethical questions.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Photoreceptors and Visual Pathways
Glaucoma: Overview
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment

